Dr. Riedel is president and CEO of Aptinyx, as well as a member of the company’s board of directors. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals, Cerevel Therapeutics, Eton Pharmaceuticals, and the Illinois Biotechnology Innovation Organization. He served on the board of directors of Ariad Pharmaceuticals until the company was acquired in February 2017. Dr. Riedel is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council. He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine and, prior to moving into industry, was an associate professor of medicine at Boston University School of Medicine and a visiting professor at the Massachusetts Institute of Technology. Dr. Riedel received a Diploma and Ph.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University.
Ms. Adams is vice president of human resources and administration at Aptinyx. She has over 24 years of experience in the healthcare industry, which includes 15 years in human resources. Previously, Ms. Adams was vice president of human resources at Naurex. Prior to joining Naurex, she served as senior director of human resources for Durata Therapeutics where she managed HR planning and operations in support of the commercial launch of Dalvance®. Ms. Adams has also led human resources functions at SagePath Medical, BioSante Pharmaceuticals, Lundbeck Inc., and Takeda Pharmaceuticals North America. Ms. Adams earned a B.A. in psychology from Columbia College and an M.S. in human resources from Loyola University Chicago.
Mr. Estupinan is vice president of finance and accounting and controller at Aptinyx, with responsibilities that include developing, executing, and overseeing the accounting and financial processes to support the company. Mr. Estupinan was part of the team at the predecessor company, Naurex, and has been with Aptinyx since the formation of the company. In his previous position at Aptinyx, as senior director of finance and accounting, he played a lead role in the IPO of the company in 2018. Prior, he was the finance reporting manager at Naurex and was involved in the acquisition of the company by Allergan. Before joining Naurex, Mr. Estupinan held roles of increasing responsibility at Durata Therapeutics and Abbott Laboratories. Mr. Estupinan began his career at Deloitte. He holds a B.A. with concentration in finance and accounting from Indiana University, Fort Wayne and earned his CPA in Indiana.
Dr. Gutierrez is senior vice president, medical and pharmacovigilance at Aptinyx. Prior to joining Aptinyx in 2020, Dr. Gutierrez was vice president of clinical development and pharmacovigilance at Marinus Pharmaceuticals. Previously, he held global senior leadership positions in neuroscience clinical development, medical affairs, and project management at Takeda, Janssen, Novartis, Bristol Myers Squibb, and Covance, in addition to a number of other biopharmaceutical companies. Dr. Gutierrez is a graduate of the National Autonomous University of Mexico Medical School, and was a resident in psychiatry and research fellow at Harvard Medical School. He was a Fogerty International Fellow at the National Institutes of Health, where he conducted trials with novel treatments for psychiatric conditions and in brain imaging at the Experimental Therapeutics Branch, NIMH.
Dr. Khan is vice president of chemistry research and development at Aptinyx. Prior to Aptinyx, he was vice president of chemistry research and development at Naurex. Dr. Khan has over 20 years’ experience as a senior chemist at several biotechnology companies, including Elan and Gliatech. Dr. Khan has discovered and developed multiple novel central nervous system molecules that have entered human clinical trials, including many NMDA receptor modulators. Dr. Khan received a B.S. and B.Ed. from the Regional Institute of Education, Bhopal, India, and an M.S. and Ph.D. from Kanpur University in India. He was a postdoctoral fellow at the Indian Institute of Technology, Kanpur, India.
Mr. Khanna is chief financial officer and chief business officer of Aptinyx, with responsibilities that include finance, corporate and business development, alliance management, legal, and communications. He was previously vice president of corporate development at Naurex and managed its financing and transaction efforts, culminating in the company’s acquisition by Allergan. Prior to Naurex, Mr. Khanna served as director of business development at Vanda Pharmaceuticals. He was formerly a member of the cardiology strategic marketing team at Cordis Corporation, a Johnson & Johnson company. Earlier, Mr. Khanna was a strategy consultant with the Palladium Group and with the Strategic Advisory Services practice of Ernst & Young (now Capgemini). He serves on the board of directors of the Illinois Biotechnology Innovation Organization. Mr. Khanna received a B.S. in finance and B.A.S. in systems engineering from the University of Pennsylvania, as well as an M.B.A. from the Wharton School.
Dr. Kidd is chief operating officer of Aptinyx. Prior to joining Aptinyx in 2017 as chief commercial officer, he was with Baxter International for over ten years, most recently as senior vice president of strategy and business development. Previously he held a number of commercial leadership positions including general manager of Baxter Canada, global franchise head for surgical care, and general manager of US anesthesia and cardiovascular. Before joining Baxter he worked at The Boston Consulting Group both in London and then Chicago focused on pharmaceutical and other healthcare clients. Dr. Kidd received a BM BCh medical degree from the University of Oxford and a BA in medical sciences from the University of Cambridge.
Dr. King is senior vice president, clinical development at Aptinyx. Prior to joining Aptinyx, she served in senior leadership roles at Levo Therapeutics, AbbVie, Takeda, Veeva Systems, and Abbott, where she was responsible for clinical projects and various global functions. Dr. King teaches courses in the clinical research and regulatory compliance program at the University of Chicago Graham School. She earned a B.S. in biochemistry from the University of Notre Dame and later received an M.A. in Health Care Ethics and a Ph.D. in Philosophy from Loyola University in Chicago.
Chairman of the Board
Founder and Managing Director, Longitude Capital
Executive Vice President and Chief Strategy Officer, AbbVie Inc.
Partner and Head of Venture / Growth Equity Investments, Adams Street Partners
Retired CFO, Baxter International Inc. and Baxalta Inc.
Managing Director, Bain Capital Life Sciences
President and CEO, Aptinyx
Retired Principal Deputy Commissioner of FDA